Open Access
ISSN: 2321-8681
Volume-9, Issue-1 (January-June)
2022
Review On Mab’s boon for Covid – 19
Correspondence: rohit.kale242@gmail.com
Abstract
Covid 19 virus called severe acute respiratory syndrome (SARS-CoV-2) contains spike proteins that assist the virus in entering host cells. Scientific community from the entire world is working to find an effective treatment for SARS-CoV-2. By using modern biotechnology treatment, monoclonal antibodies (MAbs) are being designed and developed to block a particular pathway of SARS-CoV-2 infection.. Many of them target the receptor binding protein so that the interaction between virus and host cell can be prevented.
Cite this Article
Select a citation style to copy or import directly into your reference manager:
Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini (2022). Review On Mab’s boon for Covid – 19. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June). https://doi.org/10.5281/zenodo.6620700
Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini, 2022. Review On Mab’s boon for Covid – 19. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June).
Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini. "Review On Mab’s boon for Covid – 19." Research and Reviews in Biotechnology and Biosciences Volume-9, Issue-1 (January-June) (2022).
@article{rrbb_199_KaleRohit,
title = {{Review On Mab’s boon for Covid – 19}},
author = {Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini},
journal = {Research and Reviews in Biotechnology and Biosciences},
issn = {2321-8681},
year = {2022},
volume = {Volume-9, Issue-1 (January-June)},
doi = {https://doi.org/10.5281/zenodo.6620700}
}
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.